AstraZeneca plc vs Ishares Msci Brazil ETF — how do they compare? AstraZeneca plc trades at $158.74 (market cap $248.14B), while Ishares Msci Brazil ETF trades at $33.96. The key difference: AstraZeneca plc pays a 2.01% dividend while Ishares Msci Brazil ETF pays none, and Ishares Msci Brazil ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | EWZ | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $209.48 | $41.75 |
52-Week Low | $147.06 | $27.36 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
EWZ, the iShares MSCI Brazil ETF, trades at $34.04, down 3.27% on the day. The technical outlook is bearish based on moving averages, though oscillators suggest potential for a near-term bounce. Recent news highlights institutional interest, with Empowered Funds LLC and Allspring Global Investments increasing positions in Q2 2026, while analysts debate the fund's value relative to competitors like FLBR due to its higher expense ratio.
The outlook for EWZ hinges on Brazil's economic trajectory, particularly interest rate cuts and commodity prices. Opportunities exist if Brazil's growth accelerates, but risks include U.S. tariff impacts on Brazilian exports and inconsistent dividend payouts reliant on volatile commodity stocks like Petrobras and Vale.
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →